240 related articles for article (PubMed ID: 27011176)
1. Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders.
Dang L; Liu J; Li F; Wang L; Li D; Guo B; He X; Jiang F; Liang C; Liu B; Badshah SA; He B; Lu J; Lu C; Lu A; Zhang G
Int J Mol Sci; 2016 Mar; 17(3):428. PubMed ID: 27011176
[TBL] [Abstract][Full Text] [Related]
2. Non-Viral Delivery System and Targeted Bone Disease Therapy.
Qadir A; Gao Y; Suryaji P; Tian Y; Lin X; Dang K; Jiang S; Li Y; Miao Z; Qian A
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699924
[TBL] [Abstract][Full Text] [Related]
3. Development of Bone Targeting Drugs.
Stapleton M; Sawamoto K; Alméciga-Díaz CJ; Mackenzie WG; Mason RW; Orii T; Tomatsu S
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28644392
[TBL] [Abstract][Full Text] [Related]
4. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders.
Sawamoto K; Álvarez JV; Herreño AM; Otero-Espinar FJ; Couce ML; Alméciga-Díaz CJ; Tomatsu S
Curr Osteoporos Rep; 2020 Oct; 18(5):515-525. PubMed ID: 32845464
[TBL] [Abstract][Full Text] [Related]
5. Bone-seeking agents for the treatment of bone disorders.
Cawthray J; Wasan E; Wasan K
Drug Deliv Transl Res; 2017 Aug; 7(4):466-481. PubMed ID: 28589453
[TBL] [Abstract][Full Text] [Related]
6. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents.
Zhang S; Gangal G; Uludağ H
Chem Soc Rev; 2007 Mar; 36(3):507-31. PubMed ID: 17325789
[TBL] [Abstract][Full Text] [Related]
7. The Role of MicroRNAs in Bone Metabolism and Disease.
Gao Y; Patil S; Qian A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32846921
[TBL] [Abstract][Full Text] [Related]
8. [Frontiers in Live Bone Imaging Researches. Novel drug discovery by means of intravital bone imaging technology].
Ishii M
Clin Calcium; 2015 Jun; 25(6):907-13. PubMed ID: 26017869
[TBL] [Abstract][Full Text] [Related]
9. Targeting strategies for bone diseases: signaling pathways and clinical studies.
Xu H; Wang W; Liu X; Huang W; Zhu C; Xu Y; Yang H; Bai J; Geng D
Signal Transduct Target Ther; 2023 May; 8(1):202. PubMed ID: 37198232
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
12. Lessons from rare diseases of cartilage and bone.
Gallagher JA; Ranganath LR; Boyde A
Curr Opin Pharmacol; 2015 Jun; 22():107-14. PubMed ID: 25978274
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticulate platforms for targeting bone infections: meeting a major therapeutic challenge.
Santos-Ferreira I; Bettencourt A; Almeida AJ
Nanomedicine (Lond); 2015; 10(20):3131-45. PubMed ID: 26446355
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticulate delivery systems for antiviral drugs.
Lembo D; Cavalli R
Antivir Chem Chemother; 2010; 21(2):53-70. PubMed ID: 21107015
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapies in bone metastasis.
Clément-Demange L; Clézardin P
Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
[TBL] [Abstract][Full Text] [Related]
17. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties.
Carbone EJ; Rajpura K; Allen BN; Cheng E; Ulery BD; Lo KW
Nanomedicine; 2017 Jan; 13(1):37-47. PubMed ID: 27562211
[TBL] [Abstract][Full Text] [Related]
18. [Targeted therapy for mineral and bone disorder].
Komaba H; Fukagawa M
Nihon Jinzo Gakkai Shi; 2016; 58(4):581-6. PubMed ID: 27416702
[No Abstract] [Full Text] [Related]
19. Bisphosphonate treatment of pediatric bone disease.
Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
[TBL] [Abstract][Full Text] [Related]
20. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
